Hybridize Therapeutics is developing RNA therapeutics to treat kidney diseases. Current focus areas are the BK virus- and fibrosis programs. The BK-virus program aims to develop an antisense oligonucleotide therapy to supress virus expression after a kidney transplantation.

The company uses the Mibiton lease fund to equip the R&D laboratories.